Therapeutic Development Of A Novel EphA4 Antagonist For Spinal Cord Injuries
Funder
National Health and Medical Research Council
Funding Amount
$687,105.00
Summary
Spinal cord injuries impose a significant burden on patients and their carers. At present, there are no treatments for spinal cord injury that provide functional improvement. This research program will develop a novel therapeutic molecule, EphA4-Fc, which promotes axonal regeneration and delivers significant functional improvement. We will determine the most effective protocol for EphA4-Fc administration and the physiological and functional outcomes of these treatment regimes.
Elastaderm: An Improved Human Skin Substitute For Treating Burns
Funder
National Health and Medical Research Council
Funding Amount
$326,316.00
Summary
We will focus on proof of concept needed for the commercialisation of improved dermal replacements designed to repair severe skin burns. These novel dermal replacements are a substantial development of and improvement beyond existing technology because they are intended to reduce wound contraction and increase elasticity.
Development Of Monoclonal Antibody Therapy For Treating Wounds
Funder
National Health and Medical Research Council
Funding Amount
$573,354.00
Summary
Chronic wounds, diabetic ulcers, injuries in response to trauma, burns and scalds form a medical need which will only expand as the population ages and the diabetic epidemic grows. In our studies, we have shown that Flightless I (Flii), an actin-remodelling protein, is a negative regulator of wound healing. We are developing monoclonal antibodies as a new therapy for reducing Flii levels in wounds which leads to improved wound repair outcomes.
Novel Silver Nanoparticle Coatings For The Prevention Of Infection Of Biomedical Implants And Devices
Funder
National Health and Medical Research Council
Funding Amount
$455,305.00
Summary
This project targets infections associated with implants and biomedical devices such as catheters, pacemaker leads, knee and hip implants, by the development and evaluation of coatings delivering antibacterial silver ions. The novel coating method is more uniform and reproducible and can be applied to a wide range of biomedical implants and devices. The novel coatings will be tested for antimicrobial effectiveness and safety using cell and tissue culture methods and animal clinical studies.
Development And Application Of A Pressure-sensing Electropalatograph For The Assessment And Treatment Of Speech Disorder
Funder
National Health and Medical Research Council
Funding Amount
$200,750.00
Summary
A multidisciplinary team of researchers aim to develop a unique, advanced, computer-based speech device that speech pathologists can use to assess and treat a variety of speech disorders. The device will record the location, timing and pressure of tongue contacts against the roof of the mouth (palate) during speech using innovative sensors embedded in an artificial plate placed over the roof of the mouth. State-of-the-art 3D graphics will be used to display tongue-to-palate contacts to both spee ....A multidisciplinary team of researchers aim to develop a unique, advanced, computer-based speech device that speech pathologists can use to assess and treat a variety of speech disorders. The device will record the location, timing and pressure of tongue contacts against the roof of the mouth (palate) during speech using innovative sensors embedded in an artificial plate placed over the roof of the mouth. State-of-the-art 3D graphics will be used to display tongue-to-palate contacts to both speech pathologist and patient.Read moreRead less
The Development Of A Cross-strain And Cross-subtype Pre Pandemic Influenza Vaccine Using Savine Technology
Funder
National Health and Medical Research Council
Funding Amount
$159,500.00
Summary
The flu vaccines in use today work by inducing antibodies to surface proteins. Flu causes disease every year but occasionally a new strain arises that is distincly differnet from previous strains and can cause wides spread disease and deaths worldwide. Our new approach is to increase the level of T cells that can recognise and kill flu infected cells from all flu strains.
Neuropathic Pain Drugs Based On The Endogenous Opioid Peptide Endomorphin 1.
Funder
National Health and Medical Research Council
Funding Amount
$209,470.00
Summary
We have developed a new pain drug based on the natural pain killing opioid peptide, Endomorhin 1. The new drug exhibits activity similar to morphine and gabapentin against neuropathic pain in animals but seems to act through a different mechanism. We will complete our preclinical investigation of this compound by assessing its side effect profile and tolerence inducing properties in animals. We will also continue our development of an orally active analogue of this important peptide.
Development Of Flightless Antibody Therapy For Treating Wounds
Funder
National Health and Medical Research Council
Funding Amount
$194,071.00
Summary
Chronic wounds, diabetic ulcers, injuries in response to trauma, burns and scalds form a medical need which will only expand as the population ages and the diabetic epidemic grows. In our studies, we have shown that Flightless I (FliI), an actin-remodelling protein, is a negative regulator of incisional wound healing. We are now developing a new antibody therapy to reduce FliI levels in wounds thereby leading to improved wound repair outcomes.
Studies Of Metabolites Of Synthetic Flavonols For The Treatment Of Cardiovascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$207,440.00
Summary
Cardiovascular disease, including heart attack and stroke, is the leading killer of Australians. A promising new drug, NP202, can reduce the amount of tissue damaged from a heart attack; however, its mechanism of action remains obscure. NP202 is metabolized to a range of compounds, one of which is partly responsible for its beneficial effects. In this project we will identify other metabolites of NP202 and characterize their biological activity to gain insight into its mechanism of action.
Ocular Implant For The Treatment Of Bacterial Endophthalmitis
Funder
National Health and Medical Research Council
Funding Amount
$483,446.00
Summary
We seek to develop an ocular implant for the treatment of bacterial endophthalmitis. The implant will be a small device that can be administered directly to the affected ocular cavity to release an antibiotic in a controlled manner to clear any infection. The implant will erode and leave no residue. It will be produced from a novel drug-polymer conjugate technology that allows polymer devices that comprise >50% drug to be made.